High phosphorous intake associated with increased risk of lethal prostate cancer
the ONA take:
According to a new study published in the American Journal of Clinical Nutrition, phosphorous is independently associated with the risk of developing lethal and high-grade prostate cancer.
Researchers identified nearly 48,000 men who reported their diet in 1986 and every 4 years thereafter. During the 24-year follow-up, 5,861 participants developed prostate cancer, 789 of which were lethal cancers. Results showed phosphorous intake was linked with a greater risk for developing prostate cancer, including lethal and high-grade disease.
This association was independent of calcium and dairy, fish, red meat, and white meat intake. In addition, high calcium intake was associated with an elevated risk for developing advanced-stage and high-grade disease 12 to 16 years after exposure.
High phosphorous intake was linked with an increased risk for developing advanced-stage and high-grade prostate cancer 0 to 8 years after exposure. Foods high in phosphorous include: seeds, lentils, cheese, colas, shellfish, and yogurt.
Phosphorous is independently associated with the risk of developing lethal and high-grade prostate cancer.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|